Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Tyler Dickerson, PharmD, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Devin Haddad, Avirup Guha, Kyle Porter, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, John C. Byrd, MD, Daniel Addison, Farrukh T. Awan, MD MS

Blood (2018) 132 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2018-99-110345

Published: 2018

Journal Articles

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Kami J. Maddocks, MD, Farrukh T. Awan, MD MS, Ying Huang, MA, MS, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MD MS, Samantha Jaglowski, MD MPH, Basem M. William, MRCP, MD, Kristie A. Blum, MD, Beth A. Christian, MD

Blood (2018) 132 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2018-99-117172

Published: 2018

Journal Articles

Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Blood (2018) 132 (Supplement 1): 4414.

https://doi.org/10.1182/blood-2018-99-112971

Published: 2018

Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 693.

https://doi.org/10.1182/blood-2018-99-114169

Published: 2018

Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2018-99-110477

Published: 2018

Journal Articles

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Elizabeth Kander, MD, Qiuhong Zhao, MS, Tracy Wiczer, John C. Byrd, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Tzu-Fei Wang, MD

Blood (2018) 132 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2018-99-110556

Published: 2018

Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2018-99-116338

Published: 2018

Journal Articles

Analysis of Healthcare Provider Practice Patterns from Individual Patient Cases Entered into an Online Treatment Decision Tool for Chronic Lymphocytic Leukemia (CLL)

Kristen M Rosenthal, PhD, Farrukh T. Awan, MD MS, Steven Coutre, MD, Jeffrey A. Jones, MD MPH, MBA, Jeffrey P. Sharman, MD, Kevin L Obholz, PhD, Andrew D. Zelenetz, MD PhD

Blood (2017) 130 (Supplement 1): 5614.

https://doi.org/10.1182/blood.V130.Suppl_1.5614.5614

Published: 2017

Journal Articles

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

Kerry A. Rogers, MD, Ying Huang, MA, MS, Emily Dotson, PharmD, Jordan Lundberg, PharmD, Leslie Andritsos, MD, Farrukh T. Awan, MD MS, Jeffrey A. Jones, MD MPH, MBA, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 5345.

https://doi.org/10.1182/blood.V130.Suppl_1.5345.5345

Published: 2017

Journal Articles

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

Shuchao Qin, MBBS, Austin Young Shull, Qimei Han, MBBS, Lirong Pei, Farrukh T. Awan, MD MS, Wei Xu, Jianyong Li, MD PhD, Huidong Shi

Blood (2017) 130 (Supplement 1): 3811.

https://doi.org/10.1182/blood.V130.Suppl_1.3811.3811

Published: 2017

Journal Articles

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy Stark, MAS, Farrukh T. Awan, MD MS, Kami J. Maddocks, MD, Jennifer A. Woyach, MD, Thomas Whitlow, BA, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, MBA

Blood (2017) 130 (Supplement 1): 431.

https://doi.org/10.1182/blood.V130.Suppl_1.431.431

Published: 2017

Journal Articles

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Mojgan Jianfar, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD MPH, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 432.

https://doi.org/10.1182/blood.V130.Suppl_1.432.432

Published: 2017

Journal Articles

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Kerry A. Rogers, MD, Mousa Luay, MD, Qiuhong Zhao, MS, Tracy Wiczer, PharmD, Lauren Levine, PharmD, El Boghdadly Zeinab, MBBCh, James S. Blachly, MD, John C. Byrd, MD, Tomas Guerrero, MD, Jeffrey A. Jones, MD MPH, MBA, Shindiapina Polina, MD PhD, Audrey Sigmund, MD, Matthew Sullivan, MD, Farrukh T. Awan, MD MS, Jennifer A. Woyach, MD

Blood (2017) 130 (Supplement 1): 830.

https://doi.org/10.1182/blood.V130.Suppl_1.830.830

Published: 2017

Journal Articles

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Farrukh T. Awan, MD MS, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Jeffrey Jones, MD, Leslie Andritsos, MD, Natarajan Muthusamy, DVM,PhD, Barbara Andersen, PhD, John C. Byrd, MD

Blood (2017) 130 (Supplement 1): 1748.

https://doi.org/10.1182/blood.V130.Suppl_1.1748.1748

Published: 2017

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

Blood (2017) 130 (Supplement 1): 498.

https://doi.org/10.1182/blood.V130.Suppl_1.498.498

Published: 2017

Journal Articles

Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia

Emily McWilliams, Jennifer M Mele, MS, Faraz Fiazuddin, Carolyn Cheney, BS, Natarajan Muthusamy, DVM, PhD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1289.

https://doi.org/10.1182/blood.V126.23.1289.1289

Published: 2015

Journal Articles

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

Jeff P. Sharman, MD, Andrei R. Shustov, MD, Mitchell R. Smith, MD PhD, Thomas E. Boyd, MD, Christopher Hagenstad, MD, Kathryn S. Kolibaba, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Jing Hu, PhD, Anita Reddy, PhD, Siddhartha Mitra, MDPhD, Christopher A. Yasenchak, MD, Farrukh T. Awan, MD MS

Blood (2015) 126 (23): 1744.

https://doi.org/10.1182/blood.V126.23.1744.1744

Published: 2015

Journal Articles

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Galena Salem, MD, Deborah M. Stephens, DO, Leslie A. Andritsos, MD, Farrukh T. Awan, MD MS, John C. Byrd, MD, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, Jeffrey A. Jones, MD MPH

Blood (2015) 126 (23): 2951.

https://doi.org/10.1182/blood.V126.23.2951.2951

Published: 2015

Journal Articles

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Jennifer R Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Arthur P. DeCillis, MD, MS, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 2683.

https://doi.org/10.1182/blood.V118.21.2683.2683

Published: 2011

Journal Articles

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Devi D Morrison, Samith Thomas Kochuparambil, David Deremer, Ethan Speir, Kristen Sterling, Meghan Sterrett, Vamsi Kota, MBBS, Anand P. Jillella, MD, Farrukh T Awan, MD, MS

Blood (2011) 118 (21): 4468.

https://doi.org/10.1182/blood.V118.21.4468.4468

Published: 2011

NARROW

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Analysis of Healthcare Provider Practice Patterns from Individual Patient Cases Entered into an Online Treatment Decision Tool for Chronic Lymphocytic Leukemia (CLL)

Ingle-Institutional Experience with the Use of PD-1 Inhibitors for the Treatment of Richter's Syndrome

CDK7 Inhibitor THZ1 Inhibits Glycolytic Metabolism By Suppressing HIF1α Activity in Chronic Lymphocytic Leukemia

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia: The Phase 1b/2 ACE-CL-003 Study

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

Targeting the Tumor Evasion Interaction of NKG2A and Its Ligand HLA-E Increases Natural-Killer Cell Activity in Chronic Lymphocytic Leukemia

Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling

A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Defining Treatment Paradigms for BK Virus-Induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell Transplant Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only